The risk of total myopericarditis following the COVID-19 vaccine is very low, affecting 18 people per million vaccines. A new study published in Lancet Respiratory Medicineproves that this risk is similar to or less than following the COVID-19 vaccine than other non-COVID-19 vaccines.
The researchers analyzed international data, looking at more than 400 million vaccines, to compare the risk of mypericarditis after the COVID-19 vaccine and other diseases such as colds and flu. They found no significant difference in statistically significant incidence of myopericarditis following COVID-19 injection (18 doses per million doses) and other doses (56 doses per million doses).
“Our research shows that the overall risk of myopericarditis appears to be no different for this newly approved group of COVID-19 vaccines, compared to other vaccines. And these findings should be strengthened. public trust in the safety of COVID-19 injections, ”said Dr. Kollengode Ramanathan, a cardiologist at the National University Hospital, Singapore, and a qualified author.
Myopericarditis is a condition that causes inflammation of the heart muscle and, in some cases, severe permanent damage to the heart. It is usually caused by a virus but can also occur after vaccination in rare cases. There have been reports of myopericarditis following the injection of COVID-19-based mRNA, especially in adolescents and young adults. This study aims to determine whether this report increase was due to a significant increase in the occurrence or outcome of improved reporting and bias memory.
The researchers examined more than 20 studies from international data sources with reports of myopericarditis events after each vaccination period between January 1947 and December 2021. Of these, 11 studies looked specifically at COVID-19 prevention, which covers more than 395 million COVID-19 vaccines — nearly 300 million of which are mRNA injections. Other studies have included other vaccines such as rabies (2.9 million doses), influenza (1.5 million doses), and others (5.5 million doses).
The incidence of myopericarditis after COVID-19 injection is 18 times per million doses. Of all the other vaccines combined, the number of myopericarditis was 56 times per million doses.
Of the COVID-19 injections, the risk of myopericarditis was higher for those who received mRNA vaccine (22.6 per million doses) compared to those who did not receive mRNA (market 7.9 per million doses). The cases reported were also higher in people under 30 years of age (40.9 cases per million doses), men (23 cases per million doses), and follow-up of the second dose of COVID-19 vaccine (market 31.1 per million).
To put the study in context with the risk of myopericarditis after exposure to COVID-19, the authors conducted a post-study study. Of the 2.5 million patients hospitalized with COVID-19, most had a clinical or radiological suspicion of mypericarditis, 1.1% had myopericarditis. However, while these statistics provide useful thinking, the authors note that the results may not be directly related to the number of mypericarditis cases followed by the COVID-19 injection due to different parts of the measurement.
“Occurrence of myopericarditis following non-COVID-19 immunization may suggest that myopericarditis is a result of inflammatory diseases caused by each vaccine and is not specific to SARS-CoV-2. in the COVID-19 vaccine or infection, ”said Dr. Jyoti Somani, an infectious diseases an expert at the National University Hospital, Singapore, and author ” , severe illness, and death from COVID -19. “
The authors acknowledge some shortcomings with this study, particularly noting that the study included very young children under the age of 12 who were recently eligible for immunization, and the results of this study may not be accurate for this age group. . In addition, comparisons were made in different cases for different vaccines. The research tools may be different or not available which results in a reduction in case reports in the initial study.
Writing a related commentary, Margaret Ryan of the National Institutes of Health and Clinical Professor at the University of California San Diego, USA, who did not participate in the study, said: “Reports of unforeseen events – although infrequent and limited to selective. Sections of vaccine recipients — they have the potential to undermine the effectiveness of the vaccine at an important time in response to the disease. They emphasize that the benefits of vaccination outweigh the risks in the middle of the current epidemic. science and public health strategies must continue to improve. Alternative prevention platform, vaccinesor prevention The schedule may reduce the risk of abnormalities after vaccination, and they must be considered in the context of changing the risk of infection. ”
Myopericarditis is followed by COVID-19 prevention and non-COVID-19 prevention: a systematic review and metaanalysis, Lancet Respiratory Medicine (2022). www.thelancet.com/journals/lan… (22) 00059-5 / fulltext
hintMyopericarditis after injection of COVID-19 is rare, found international study (2022, April 11) recovered 11 April 2022 from https://medicalxpress.com/news/2022-04-myopericarditis-covid-vaccination -rare-international.html
This document is copyrighted. Apart from any genuine transaction for the purpose of personal analysis or investigation, no part may be reproduced without our written permission. Content is provided for informational purposes only.
Myopericarditis following COVID-19 vaccination is rare, finds international study Source link Myopericarditis following COVID-19 vaccination is rare, finds international study